Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Nutr Metab Cardiovasc Dis ; 24(3): 263-70, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24418374

ABSTRACT

AIMS: To investigate the incidence of major cardiovascular complications and mortality in the first years of follow-up in patients with newly diagnosed diabetes. METHODS AND RESULTS: We examined incidence rates of hospitalization for cardiovascular reasons and death among new patients with diabetes using the administrative health database of the nine million inhabitants of Lombardy followed from 2002 to 2007. Age and sex-adjusted rates were calculated and hazard ratios (HR) were estimated with a matched population without diabetes of the same sex, age (± 1 year) and general practitioner. There were 158,426 patients with newly diagnosed diabetes and 314,115 subjects without diabetes. Mean follow-up was 33.0 months (SD ± 17.5). 9.7% of patients with diabetes were hospitalized for cardiovascular events vs. 5.4% of subjects without diabetes; mortality rate was higher in patients with diabetes (7.7% vs. 4.4%). The estimated probability of hospitalization during the follow up was higher in patients with diabetes than in subjects without for coronary heart disease (HR 1.4, 95% CI 1.3-1.4), cerebrovascular disease (HR 1.3.95% CI 1.2-1.3), heart failure (HR 1.4, 95% CI 1.3-1.4) as was mortality (HR 1.4, 95% CI 1.4-1.4). Younger patients with diabetes had a risk of death or hospital admission for cardio-cerebrovascular events similar to subjects without diabetes ten years older. CONCLUSIONS: The elevated morbidity and mortality risks were clear since the onset of diabetes and rose over time. These data highlight the importance of prompt and comprehensive patients care in addition to anti-diabetic therapy in patients with newly diagnosed diabetes.


Subject(s)
Cardiovascular Diseases/epidemiology , Diabetes Mellitus/diagnosis , Diabetes Mellitus/epidemiology , Adult , Aged , Aged, 80 and over , Angiotensin Receptor Antagonists/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Cardiovascular Diseases/drug therapy , Databases, Factual , Diabetes Mellitus/drug therapy , Female , Follow-Up Studies , Hospitalization , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Hypoglycemic Agents/therapeutic use , Incidence , Male , Middle Aged , Morbidity , Multivariate Analysis , Platelet Aggregation Inhibitors/therapeutic use , Proportional Hazards Models , Risk Factors
2.
Diabet Med ; 29(3): 385-92, 2012 Mar.
Article in English | MEDLINE | ID: mdl-21913971

ABSTRACT

AIMS: To describe trends in diagnosed diabetes prevalence, incidence and mortality from 2000 to 2007 in the most heavily populated Italian region. METHODS: We examined the prevalence and incidence rates of Type 1 and Type 2 diabetes and yearly mortality rates among individuals with diabetes from 2000 to 2007 using an administrative health database of prescription, disease-specific exemption and hospitalization records of more than 9 million inhabitants of Lombardy. Age- and sex-specific rates were calculated and temporal trends for subjects aged ≥ 30 years were analysed. RESULTS: The crude point diabetes prevalence rose from 3.0% in 2000 to 4.2% in 2007, a 40% increase. The incidence remained stable during the study period with a rate of 4/1000 per year. Overall mortality declined from 43.2/1000 in 2001 to 40.3/1000 in 2007 (6.7% decrease) at a rate slightly higher than that of the general population (4.8% decrease). Our projection in subjects aged ≥ 30 years indicates that the prevalence will rise continuously over the next years, reaching 11.1% in 2030. CONCLUSIONS: The prevalence of diabetes increased substantially between 2000 and 2007, mainly because there are more patients with a new diagnosis each year than those who die. The increase observed by 2007 almost reached the World Health Organization prediction for 2030. Our analyses suggest that the increase will continue over the next few decades. These data are important for defining the burden of diabetes in the near future, to help in planning health services and ensure proper allocation of resources.


Subject(s)
Diabetes Mellitus, Type 1/epidemiology , Diabetes Mellitus, Type 2/epidemiology , Diabetic Nephropathies/epidemiology , Diabetic Retinopathy/epidemiology , Adolescent , Adult , Age Distribution , Aged , Child , Child, Preschool , Diabetes Mellitus, Type 1/complications , Diabetes Mellitus, Type 1/mortality , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/mortality , Diabetic Nephropathies/mortality , Diabetic Retinopathy/mortality , Female , Health Planning , Humans , Incidence , Infant , Italy/epidemiology , Male , Middle Aged , Mortality/trends , Prevalence , Retrospective Studies , Young Adult
3.
J Clin Pharm Ther ; 34(4): 377-86, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19583670

ABSTRACT

PURPOSE: To estimate the prevalence of potentially severe drug-drug interactions (DDIs) and their relationship with age, sex and number of prescribed drugs. METHODS: We analysed all prescriptions dispensed from 1 January 2003 to 31 December 2003 to individuals aged 65 or more registered under the Local Health Authority of Lecco, a northern Italian province with a population of almost 330 000 persons. Elderly who received at least two co-administered prescriptions were selected to assess the presence of DDIs. RESULTS: The prevalence of potentially severe DDIs was 16%, and rose with increasing patient's age and number of drugs prescribed. At multivariate analysis, the adjusted odds ratios rose from 1.07 (95% CI 1.03-1.11) in patients aged 70-74 to 1.52 (95% CI 1.46-1.60) in those aged 85 or older. Elderly taking more than five drugs on a chronic basis had a statistically significant higher risk of sever DDIs than those receiving less than 3 or 3-5 such drugs. CONCLUSIONS: The elderly constitutes a population at high risk of DDIs. As physicians still have some difficulty in managing this problem, it is essential to highlight for them, which factors raise the risk of DDIs.


Subject(s)
Drug Interactions , Polypharmacy , Prescription Drugs/adverse effects , Age Factors , Aged , Aged, 80 and over , Databases, Factual , Female , Humans , Italy , Male , Multivariate Analysis , Retrospective Studies , Sex Factors
4.
Assist Inferm Ric ; 18(1): 25-9, 1999.
Article in Italian | MEDLINE | ID: mdl-10969555

ABSTRACT

The innovative experience of the participation of a Registered Nurse in the Hospital Therapeutic Committee is described. The occasion for the participation was the drawing up of the Hospital Therapeutic Reference Book. The nurse had an active role in the identification of problems related to the practical use of drugs. Problems emerged, concerning the choices of the Committee and the implications for nursing care are discussed. The nurse can have a positive impact and her/his presence in the Therapeutic Committees should be mandatory.


Subject(s)
Nursing Staff, Hospital/organization & administration , Patient Care Team/organization & administration , Pharmacy and Therapeutics Committee/organization & administration , Decision Making, Organizational , Drug-Related Side Effects and Adverse Reactions , Humans , Organizational Objectives , Problem Solving
5.
Arch Pharm (Weinheim) ; 331(11): 368-70, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9881061

ABSTRACT

In order to obtain an insight into the mode of binding at the for-Met-Leu-Phe-OH (fMLP) receptor, three fMLP-OMe analogs (1-3) were synthesized in which the Met residue was substituted by Gln 1, Asn 2, and Ser 3. We evaluated the influence of the charge variation and/or the shift of its position on neutrophil biological responses.


Subject(s)
Chemotactic Factors/pharmacology , N-Formylmethionine Leucyl-Phenylalanine/analogs & derivatives , N-Formylmethionine Leucyl-Phenylalanine/pharmacology , Receptors, Immunologic/drug effects , Receptors, Peptide/drug effects , Chemotactic Factors/chemistry , Chemotactic Factors/metabolism , Humans , N-Formylmethionine Leucyl-Phenylalanine/chemistry , N-Formylmethionine Leucyl-Phenylalanine/metabolism , Neutrophils/drug effects , Receptors, Formyl Peptide , Receptors, Immunologic/metabolism , Receptors, Peptide/metabolism , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...